Medicinal products with Rituximab as infusion solution concentrate
Notice title: Arzneimittel mit dem Wirkstoff Rituximab - in der Darreichungsform Infusionslösungskonzentrat (ATC: L01FA01)
Conclusion of non-exclusive discount agreements for finished medicinal products with the active ingredient Rituximab as infusion solution concentrate (ATC: L01FA01): under an open-house model, contract conclusion possible at any time under the same conditions, no individual contract negotiations. Earliest contract start date is January 1, 2027, maximum contract duration 24 months, contract ends on December 31, 2028. This is not a public contract according to § 103 GWB.
Never miss a tender again
We send you 3 current matches that fit your company.
Tender documents
- Portal — LOT-0001NON-RESTRICTED-DOCUMENT
- TED HTML — 799123-2026HTML
- TED PDF — 799123-2026PDF
- TED XML — 799123-2026XML
Unlock documents for free
Enter your email address. If you confirm, we will also send you 3 similar tenders.